Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urogenital Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1

Interventions

padeliporfin 5Nivolumab 5Ipilimumab 4Sunitinib 3Specimen Handling 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Abiraterone Acetate 3pembrolizumab 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2abiraterone 2Surveys and Questionnaires 2Radiation Dose Hypofractionation 2Pluvicto 2Paclitaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 2vinflunine 1valrubicin 1tislelizumab 1temsirolimus 1sipuleucel-T 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Powders × Genitourinary × Clear all
NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

NanOlogy, LLC

Phase 2 Terminated
1 enrolled 5 charts
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡